Trabectedin and Radiotherapy in Endometrial Stromal Sarcoma: A Case Report.

ABSTRACT:

Introduction

Endometrial stromal sarcoma (ESS) is a rare tumor that remains a diagnostic and therapeutic challenge to physicians worldwide. The metastatic setting implies a poor prognosis, with a 5-year survival rate below 40%. Patients with advanced-stage high-grade ESS (HG-ESS) have limited therapeutic options, often involving various chemotherapy regimens.

Case presentation

This report depicts the case of a 47-year-old female diagnosed with HG-ESS. She underwent several lines of treatment starting with radiotherapy and brachytherapy, followed by multiple lines of treatment including trabectedin over several months. After retreatment with trabectedin and achieving disease stabilization for 10 months, treatment was optimized by trabectedin combined with radiotherapy, leadin

SUBMITTER: Carrasco Garcia I 

PROVIDER: S-EPMC10783890 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature